Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection

Clinical and Experimental Immunology

Volumn 105, Issue 1, 1996, Pages 52-58

  Bocher W O ^a   Herzog Hauff, S ^a   Herr, W ^a   Heermann, K ^b   Gerken, G ^a   Meyer Zum Buschenfelde K H ^a   Lohr H F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

anti HBs antibodies; cellular response; ELISPOT; HBs vaccine; immunoregulation

Indexed keywords

CD4 ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOBLOTTING; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; T LYMPHOCYTE;

EID: 0030036180     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-732.x     Document Type: Article

References (33)

1. Bertoletti A, Ferrari C, Fiaccadori F et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88:10445-9.
2. Löhr HF, Gerken G, Schlicht HJ, Meyer zum Büschenfelde KH, Fleischer B. Low frequency of cytotoxic T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993; 168:1133-9.
3. Tsai SL, Chen PJ, Lai MY et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992; 89:87-96.
4. Barnaba V, Franco A, Alberti A, Balsano C, Benvenuto R, Balsano F. Recognition of hepatitis B virus envelope proteins by liver infiltrating T lymphocytes in chronic HBV infection. J Immunol 1989; 143:2650-5.
5. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:1565-70.
6. Szumness W, Stevens CE, Zang EA, Hurley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1:377-85.
7. Wainwright RB, McMahon BJ, Bulkow LR et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik eskimo population. JAMA 1989; 261:2362-6.
8. Filion LG, Saginur R, Szczerbak N. Humoral and cellular immune responses by normal individuals to hepatits B surface antigen vaccination. Clin Exp Immunol 1988; 71:405-9.
9. Salazar M, Deulofeut H, Granja C et al. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics 1995; 41:366-74.
10. Van Hattum J. Schreuder GM, Schalm SW. HLA antigens in patients with various courses after hepatitis B virus infection. Hepatology 1987; 7:11-14.
11. Thursz MR, Kwiatkowski D, Allsopp CEM, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995; 332:1065-9.
12. Dusheiko GM, Hoofnagle JH, Cooksley WG, James SP, Jones EA. Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest 1983; 71:1104-13.
13. Barnaba V, Valesini G. Levrero M, Zaccari C, Van Dyke A, Falco M, Musca A, Balsano F. Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol 1985; 66:259-66.
14. Manns M. Autoantibodies and antigens in liver disease - updated. Hepatology 1989; 9:272-80.
15. Heermann K, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 1984; 52:396-402.
16. Milich DR. T- and B-cell recognition of hepatitis B viral antigens. Immunol Today 1988; 9:380-6.
17. Böyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21:1-6.
18. Czerkinsky C, Nilsson LA, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase enzyme linked immunospot (ELISPOT) assay for enumeration of specific antibody- secreting cells. J Immunol Methods 1983; 65:109.
19. Herr W, Schneider J, Lohse AW, Meyer zum Büschenfelde KH. Wölfel T. Detection and quantification of blood derived CD8-positive T-lymphocytes secreting TNF (in response to HLA A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996; in press.
20. Löhr HF, Gerken G, Michel G, Braun HB, Meyer zum Büschenfelde KH. In-vitro secretion of anti-GOR protein and anti-hepatitis C virus in patients with chronic hepatitis C. Gastroenterology 1994; 107:1443-8.
21. Chang TW, Celis E, Miller RW, Zurawski VR, Kung PC. In vitro response to HBsAg of peripheral blood lymphocytes from recipients of hepatitis B vaccine. Hepatology 1984; 4:824-9.
22. + T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis Be-minus hepatitis B virus mutants. Hepatology 1995; 22:61-68.
23. Löhr HF, Treichel U, Poralla T, Manns M, Meyer zum Büschenfelde KH, Fleischer B. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol 1992; 88:45-49.
24. Watanabe H, Okumura M, Hirayama K, Sasazuki T. HLA Bw54 DR4 Drw53 Dqw4 haplotype controls nonresponsiveness to hepatitis B surface antigen via CD8-positive suppressor T-cells. Tissue Antigens 1990; 36:69-74.
25. Barnaba V, Levrero M, Uberti G, VanDyke A, Perrone A, Musca A, Balsano F. In vitro anti-HBs antibody synthesis from antihepatitis B vaccine recipients. Clin Exp Immunol 1987; 70:283-8.
26. Fernan A, Cayzer CJR, Cooksley WGE. HBsAg-induced antigen specific T and B lymphocyte responses in chronic hepatitis B virus carriers and immune individuals. Clin Exp Immunol 1989; 76:222-6.
27. Slifka MK, Matloubian M. Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 1995; 69:1895-902.
28. Quiding M, Nordström I, Kilander A, Andersson G, Hanson LA, Holmgren J, Czerkinsky C. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon production and evokes local immunological memory. J Clin Invest 1991; 88:143-8.
29. Wismans PJ, Van Hattum J, De Gast GC, Endeman HJ, Poel J, Stolk B, Maikoe T, Mudde GC. The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin Exp Immunol 1989; 78:75-78.
30. Cupps TR, Gerin JL, Purcell RH, Goldsmith PK, Fauci AS. In vitro antigen-induced antibody responses to hepatits B surface antigen in man. J Clin Invest 1984; 74:1204-13.
31. Knolle P, Löhr H, Treichel U, Dienes HP, Lohse A, Schlaak J, Gerken G. Parenchymal and nonparenchymal liver cells and their interaction in the local immune response. Z Gastroenterol 1995; 33:613-20.
32. Milich DR, McLachlan A, Thornton GB, Hughes JL. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987; 329:547-9.
33. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177:1367-81.